Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants?

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Durrmeyer, Xavier ^a,c   Hovhannisyan, Shushanik ^b,c   Médard, Yves ^b,c   Jacqz Aigrain, Evelyne ^b,c   Decobert, Fabrice ^a,c   Barre, Jérome ^a,c   Alberti, Corinne ^b,c   Aujard, Yannick ^b,c   Danan, Claude ^a,c   Baud, Olivier ^b,c  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c Fondation PremUP   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; IBUPROFEN; CYP2C8 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG RESPONSE; ENZYME POLYMORPHISM; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GESTATIONAL AGE; HEART HEMODYNAMICS; HEART SURGERY; HUMAN; INFANT; MALE; PATENT DUCTUS ARTERIOSUS; PREDICTION; PREMATURITY; GENETICS; NEWBORN; PREGNANCY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ARYL HYDROCARBON HYDROXYLASES; DUCTUS ARTERIOSUS, PATENT; FEMALE; GENOTYPE; HUMANS; IBUPROFEN; INFANT; INFANT, NEWBORN; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; PREMATURE BIRTH; TREATMENT OUTCOME;

EID: 77957867767     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012329     Document Type: Article

References (47)

1. Hammerman C, Kaplan M (2001) Comparative tolerability of pharmacological treatments for patent ductus arteriosus. Drug Saf 24: 537-551.
2. Trus T, Winthrop AL, Pipe S, Shah J, Langer JC, et al. (1993) Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g. J Pediatr Surg 28: 1137-1139.
3. Palder SB, Schwartz MZ, Tyson KR, Marr CC (1987) Management of patent ductus arteriosus: A comparison of operative v pharmacologic treatment. J Pediatr Surg 22: 1171-1174.
4. Narayanan M, Cooper B, Weiss H, Clyman RI (2000) Prophylactic indomethacin: Factors determining permanent ductus arteriosus closure. J Pediatr 136: 330-337.
5. Clyman RI, Chorne N (2007) Patent ductus arteriosus: Evidence for and against treatment. J Pediatr 150: 216-219.
6. Moin F, Kennedy KA, Moya FR (2003) Risk factors predicting vasopressor use after patent ductus arteriosus ligation. Am J Perinatol 20: 313-320.
7. McCurnin D, Seidner S, Chang LY, Waleh N, Ikegami M, et al. Ibuprofeninduced patent ductus arteriosus closure: Physiologic, histologic, and biochemical effects on the premature lung. Pediatrics 121: 945-956.
8. Van Overmeire B, Touw D, Schepens PJ, Kearns GL, van den Anker JN (2001) Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin Pharmacol Ther 70: 336-343.
9. Aranda JV, Varvarigou A (1997) Pharmnacokinetics and proteine binding of intravenous ibuprofen in the premature newborn infant (1997) Acta Paediatr 86: 289-293.
10. Desfrere L, Zohar S, Morville P, Brunhes A, Chevret S, et al. (2005) Dosefinding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther 30: 121-132.
11. Hamman MA, Thompson GA, Hall SD (1997) Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 54: 33-41.
12. Garcia-Martin E, Martinez C, Ladero JM, Agundez JA (2006) Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 10: 29-40.
13. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, et al. (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11: 597-607.
14. Garcia-Martin E, Martinez C, Tabares B, Frias J, Agundez JA (2004) Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 76: 119-127.
15. Lopez-Rodriguez R, Novalbos J, Gallego-Sandin S, Román-Martínez M, Torrado J, et al. (2008) Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacol Res 58: 77-84.
16. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, et al. (2001) A new and improved population-based canadian reference for birth weight for gestational age. Pediatrics 108: E35.
17. El Hajjar M, Vaksmann G, Rakza T, Kongolo G, Storme L (2005) Severity of the ductal shunt: A comparison of different markers. Arch Dis Child Fetal Neonatal Ed 90: F419-22.
18. Martinez C, Garcia-Martin E, Blanco G, Gamito FJ, Ladero JM, et al. (2005) The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol 59: 62-69.
19. Leemann TD, Transon C, Bonnabry P, Dayer P (1993) A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp Clin Res 19: 189-195.
20. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, et al. (2002) Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 299: 25-28.
21. Totah RA, Rettie AE (2005) Cytochrome P450 2C8: Substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 77: 341-352.
22. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, et al. (2003) Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 349: 1157-1167.
23. Treluyer JM, Gueret G, Cheron G, Sonnier M, Cresteil T (1997) Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: In-vivo/in-vitro correlation and inducibility. Pharmacogenetics 7: 441-452.
24. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, et al. (2004) Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 308: 965-974.
25. Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, et al. (2001) Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88: 44-51.
26. Cogolludo AL, Moral-Sanz J, van der Sterren S, Frazziano G, van Cleef AN, et al. (2009) Maturation of O2 sensing and signaling in the chicken ductus arteriosus. Am J Physiol Lung Cell Mol Physiol 297: L619-30.
27. Agundez JA, Garcia-Martin E, Martinez C (2009) Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: Is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol 5: 607-620.
28. Rifkind AB, Lee C, Chang TK, Waxman DJ (1995) Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: Regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch Biochem Biophys 320: 380-389.
29. Node K, Huo Y, Ruan X, Yang B, Spiecker M, et al. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285: 1276-1279.
30. Imig JD (2000) Eicosanoid regulation of the renal vasculature. Am J Physiol Renal Physiol 279: F965-81.
31. Mata-Greenwood E, Chen DB (2008) Racial differences in nitric oxidedependent vasorelaxation. Reprod Sci 15: 9-25.
32. Engel SA, Erichsen HC, Savitz DA, Thorp J, Chanock SJ, et al. (2005) Risk of spontaneous preterm birth is associated with common proinflammatory cytokine polymorphisms. Epidemiology 16: 469-477.
33. Engel SA, Olshan AF, Savitz DA, Thorp J, Erichsen HC, et al. (2005) Risk of small-for-gestational age is associated with common anti-inflammatory cytokine polymorphisms. Epidemiology 16: 478-486.
34. Gibson CS, MacLennan AH, Dekker GA, Goldwater PN, Dambrosia JM, et al. (2007) Genetic polymorphisms and spontaneous preterm birth. Obstet Gynecol 109: 384-391.
35. Nelson KB, Dambrosia JM, Iovannisci DM, Cheng S, Grether JK, et al. (2005) Genetic polymorphisms and cerebral palsy in very preterm infants. Pediatr Res 57: 494-499.
36. Fontaine RH, Olivier P, Massonneau V, Leroux P, Degos V, et al. (2008) Vulnerability of white matter towards antenatal hypoxia is linked to a speciesdependent regulation of glutamate receptor subunits. Proc Natl Acad Sci U S A 105: 16779-16784.
37. Dagle JM, Lepp NT, Cooper ME, Schaa KL, Kelsey KJ, et al. (2009) Determination of genetic predisposition to patent ductus arteriosus in preterm infants. Pediatrics 123: 1116-1123.
38. Bhandari V, Zhou G, Bizzarro MJ, Buhimschi C, Hussain N, et al. (2009) Genetic contribution to patent ductus arteriosus in the premature newborn. Pediatrics 123: 669-673.
39. Ivey KN, Srivastava D (2006) The paradoxical patent ductus arteriosus. J Clin Invest 116: 2863-2865.
40. Hessol NA, Fuentes-Afflick E (2005) Ethnic differences in neonatal and postneonatal mortality. Pediatrics 115: e44-51.
41. Alexander GR, Kogan M, Bader D, Carlo W, Allen M, et al. (2003) US birth weight/gestational age-specific neonatal mortality: 1995-1997 rates for whites, hispanics, and blacks. Pediatrics 111: e61-6.
42. Hamvas A, Wise PH, Yang RK, Wampler NS, Noguchi A, et al. (1996) The influence of the wider use of surfactant therapy on neonatal mortality among blacks and whites. N Engl J Med 334: 1635-1640.
43. Farrell PM, Wood RE (1976) Epidemiology of hyaline membrane disease in the United States: Analysis of national mortality statistics. Pediatrics 58: 167-176.
44. Ranganathan D, Wall S, Khoshnood B, Singh JK, Lee KS (2000) Racial differences in respiratory-related neonatal mortality among very low birth weight infants. J Pediatr 136: 454-459.
45. Fujikura T, Froehlich LA (1966) The influence of race and other factors on pulmonary hyaline membranes. A report from the collaborative study of cerebral palsy. Am J Obstet Gynecol 95: 572-578.
46. Hulsey TC, Alexander GR, Robillard PY, Annibale DJ, Keenan A (1993) Hyaline membrane disease: The role of ethnicity and maternal risk characteristics. Am J Obstet Gynecol 168: 572-576.
47. Ross S, Naeye RL (1981) Racial and environmental influences on fetal lung maturation. Pediatrics 68: 790-795.